- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis (CPP)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 655KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 195KB)
Apremilast – November 2023
Apremilast: Tablet 30 mg, Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg; Otezla®
Last updated
1 March 2024